Six Researchers Win Grants on Shared Autoimmune Mechanisms
Awards of up to $150,000 each fund one-year pilot studies linking multiple sclerosis, type 1 diabetes and lupus.
Updated on Nov. 20, 2026 in Diabetes

Six researchers have received Common Mechanisms in Autoimmunity Insight Awards, each worth up to $150,000, to study biological pathways shared across multiple autoimmune diseases. The one-year pilot grants were established by the National Multiple Sclerosis Society, Breakthrough T1D and the Lupus Research Alliance.
Why it matters
People with one autoimmune disease have an increased likelihood of developing another, so identifying shared pathways is aimed at accelerating development of therapies that work across conditions. Applications for next year's funding round are open with a Jan. 7 deadline.
The grants are up to $150,000 each for one-year pilot projects, with one awardee analyzing data from more than 1 million individual immune cells. Whether these pilot studies will identify shared mechanisms that translate into treatments has not yet been determined.
The players
National Multiple Sclerosis Society
A U.S. nonprofit organization that funds research and services for people living with multiple sclerosis, one of the three founding partners of the awards.
Breakthrough T1D
An international nonprofit formerly known as JDRF that funds research into type 1 diabetes and its complications, one of the three founding partners of the awards.
Lupus Research Alliance
A U.S.-based nonprofit that funds lupus research with the goal of finding better treatments and a cure, one of the three founding partners of the awards.
The details
Awardees include Maya Arce of the Arc Institute in California, studying genetic risk changes in CD4-positive T-cells, and Ka Lung Cheung of the Icahn School of Medicine at Mount Sinai, testing a medication that blocks Hdac7 action in models of MS, diabetes and lupus. Thomas Pieber of the Medical University of Graz in Austria will test approved JAK inhibitors on immune cells from patients with MS, diabetes or lupus, while Ingrid Kockum of Karolinska Institutet in Sweden will combine genetic, clinical and lifestyle data.
Timeline
Jan. 7: Application deadline for next year's Common Mechanisms in Autoimmunity Insight Awards.
Big Picture
The Common Mechanisms in Autoimmunity Insight Awards, jointly established by the National Multiple Sclerosis Society, Breakthrough T1D and the Lupus Research Alliance, extends a cross-disease approach by funding pilot projects on shared immune pathways. This round's six awards continue that model, with next year's applications due Jan. 7.
Researchers hope that identifying pathways shared across MS, type 1 diabetes and lupus could lead to treatments that address more than one condition. For people already living with one autoimmune disease, the findings may eventually inform how risk of a second condition is understood and managed, though no clinical changes have been announced.
The takeaway
Because autoimmune diseases often share underlying biology, research that looks across conditions rather than one at a time may speed the search for new therapies. Readers with an autoimmune diagnosis can ask their clinicians whether any emerging studies are relevant to their care.
What happens next
Applications for next year's Common Mechanisms in Autoimmunity Insight Awards close on Jan. 7.
Further reading
For more on the research behind these shared autoimmune pathways, explore our Diabetes coverage.
Source note: This article includes information reported by Multiple Sclerosis News Today.



